Venoms to Drugs

Venom from cone snails, scorpions, spiders, snakes and other species continue to provide an immense reservoir of potent bioactive peptides that target specific enzymes, ion channels and receptors. As such they represent major sources of lead compounds for both the development of pharmacological tools and novel drugs

KEYNOTE SPEAKERS

Professor Emmanuel Bourinet

Team Leader, Neurosciences: Institut de Génomique Fonctionelle de Montpellier, France

Proposed Talk: Low-voltage gated calcium channels in pain pathwys; from mecanism to toxin identification.

 

Dr Stuart Brierley

NHMRC R.D. Wright Biomedical Fellow: Visceral Pain Group, University of Adelaide, South Australian Health and Medical Research Institute (SAHMRI), Australia

Proposed Talk: Novel targets for the treatment of chronic visceral pain.

 

Professor Brian Chait

Camille and Henry Dreyfus Professor: Rockefeller University, USA

Proposed Talk: Rapid Production of versatile nanobody repertoires. 

 

Professor Arthur Christopoulos

Professor of Pharmacology: Faculty of Pharmacy and Pharaceutical Sciences, Monash University, Australia

Proposed Talk: Allosteric targeting of G protein-coupled receptors.

 

Professor Jennifer Cochran

Associate Professor of Bioengineering, Stanford University, USA

Proposed Talk: Engineered cystine knot peptides: A new class of targeting agents.

 

Professor Mary Collins

Professor of Pharmaceutical Neuroscience, The University of Sydney, Australia

Proposed Talk: Multiple binding interfaces on nACH receptors allude to stoichiometric dependent actions of antagonists.

 

Professor Annette Dolphin

Professor of Pharmacology: University College London, England

Proposed Talk: Regulation of voltage-gated calcium channel trafficking and function of α2δ subunits.

 

Dr Sebastien Dutertre

The Institute des Biomolécules Max Mousseron, Universite de Montpellier 2, France

Proposed Talk: Revision of prey capture and defence strategies in cone snails.

 

Professor Bryan Fry

Group Leader: University of Queensland, Australia

Proposed Talk: Evolutionary toxinology: How to see the woods for the trees.

 

Professor Ray Norton

Professor: Monash Institute of Pharmaceutical Sciences, Monash University, Australia

Proposed Talk: New potassium channel blockers as treatments for autoimmune diseases: design, sysnthesis, stability and delivery.

 

Professor Baldomero Olivera

Distinguished Professor: Department of Biology, The University of Utah, USA

Proposed Talk: Conus peptides, constellation pharmacology and heteromeric channel complexes.

 

Dr Mike Pennington

President and CEO: Peptides International Inc., USA

Proposed Talk: Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.

 

Professor Anthony Purcell

Laboratory Head: Department of Biochemistry and Molecular Biology, Monash University, Australia

Proposed talk: Concerted actions and regiospecific expression of Conus foldases and enzymes underpins toxin biosynthesis.

 

Dr Jefferson Revell

Scientist II: Peptide Chemistry, MedImmune Ltd., Cambridge, U.K.

Proposed talk: Engineering Huwentoxin-IV.

 

Dr Reto Stöcklin

Founder: Atheris Laboratories

 

Professor Victor Tsetlin

Department Head: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Russia

Proposed Talk: From α-conotoxins, three-finger α-neurotoxins and Ly6 brain proteins to binding sites in nicotinic receptors

 

Dr Irina Vetter

ARC Future Fellow and Group Leader: Institute for Molecular Bioscience, Australia

Proposed talk: Peripheral mechanisms of pain - insights from venom peptide ion channel modulators.

 

 

INVITED SPEAKERS

Dr Christopher Armishaw

Assistant Member Medicinal Chemistry: Torrey Pines Institute for Molecular Biosciences

Proposed Talk: Synthetic conotoxin combinatorial libraries: discovery of novel nicotinic receptor igands for studying tobacco addiction and pain.

 

Prof Norelle Daly

Professorial Research Fellow: Australian Institute of Tropical Health and Medicine

Proposed Talk: When structure leads to activity - analysis of a novel conotoxin.

 

Dr Andrew Ellisdon

Post Doctoral Fellow: Monash University

Proposed Talk: The structural basis of stonefish toxicity - high resolution insight into a pore-forming venom.

 

Professor Robert French

Professor of Physiology and Pharmacology: University of Calgary

Proposed Talk: An archtypical channel blocker with a split personality. µ-Conotoxin actions show new complexities when inhibiting a 'simple' prokaryotic sodium channel.

 

Professor Alan Harvey

Professor of Pharmacology: University of Strathclyde, United Kingdom

Proposed Talk: From toxins to medicines: What are we doing wrong?

 

Dr Jeroen Kool

Assistant Professor: VU University Amsterdam, The Netherlands

Proposed Talk: Venom analytics for rapid identification and structural elucidation of bioactive peptides.

 

Professor Michael Parker:

Deputy Director: St Vincents Institute of Medical Research

Proposed Talk: Cholesterol-dependent cytolysins: from soluble state to membrane pore.

 

Dr Christina Schroeder

Postdoctoral Fellow: Institute for Molecular Bioscience, Australia

Prooposed Talk: Semi-enzymatic cyclisation of kappa-conotoxin PVIIA, a peptide containing the inhibitory cystine knot motif.

 

Professor Maree Smith

Executive Director: TetraQ and Group Leader, Department of Pharmacy, The University of Queensland, Australia

Proposed Talk:  Discovery and development of new pain medicines: Towards improving translational research outcomes.

 

Prof Dr Katharina Zimmermann

PD Dr Med: Department of Anesthesia, University Clinic, Friedrich-Alexander-Universität Erlangen-Nürnburg, Germany

Proposed Talk: Botulinum Toxin-A treatment reduces cold responsiveness of cutaneous C-fiber nociceptors in vitro.